

ENZO BIOCHEM INC
Form DEF 14A
November 28, 2008

SCHEDULE 14A
(Rule 14a-101)

INFORMATION REQUIRED IN PROXY STATEMENT

SCHEDULE 14A INFORMATION

Proxy Statement Pursuant to Section 14(a) of the Securities
Exchange Act of 1934 (Amendment No.)

Filed by the Registrant

Filed by a Party other than the Registrant

Check the appropriate box:

Preliminary Proxy Statement

Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

Definitive Proxy Statement

Definitive Additional Materials

Soliciting Material Under Rule 14a-12

Enzo Biochem, Inc.

(Name of Registrant as Specified In Its Charter)

(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant)

Payment of Filing Fee (Check the appropriate box):

No fee required.

Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.

1) Title of each class of securities to which transaction applies:

2) Aggregate number of securities to which transaction applies:

3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):

4) Proposed maximum aggregate value of transaction:

5) Total fee paid:

Fee previously paid with preliminary materials:

Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing.

1) Amount Previously Paid:

2) Form, Schedule or Registration Statement No.:

3) Filing Party:

4) Date Filed:

ENZO BIOCHEM, INC.

**NOTICE OF ANNUAL MEETING OF SHAREHOLDERS
TO BE HELD ON JANUARY 22, 2009**

To the Shareholders of Enzo Biochem, Inc.:

NOTICE IS HEREBY GIVEN that the 2008 Annual Meeting of Shareholders of Enzo Biochem, Inc., a New York corporation (the "Company"), will be held at The Yale Club, 50 Vanderbilt Avenue, New York, New York 10017, on January 22, 2009, at 9:00 a.m., local time (the "Annual Meeting"), for the following purposes:

1. To elect Elazar Rabbani as a Class III Director for a term of three (3) years or until his respective successor is elected and qualified;
2. To ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the Company's fiscal year ending July 31, 2009; and
3. To transact such other business as may properly come before the Annual Meeting or any adjournment thereof.

The close of business on November 25, 2008 has been fixed as the record date for the determination of shareholders entitled to notice of and to vote at the Annual Meeting. The transfer books of the Company will not be closed.

All shareholders are cordially invited to attend the Annual Meeting. Please note that you will be asked to present valid picture identification, such as a driver's license or passport, in order to attend the Annual Meeting. The use of cameras, recording devices and other electronic devices will be prohibited at the Annual Meeting.

Whether or not you expect to attend, you are requested to sign, date and return the enclosed proxy promptly. Shareholders who execute proxies retain the right to revoke them at any time prior to the voting thereof by filing written notice of such revocation with the Secretary of the Company, by submission of a duly executed proxy bearing a later date or by voting in person at the Annual Meeting of Shareholders. Attendance at the Annual Meeting will not in and of itself constitute revocation of a proxy. Any written notice revoking a proxy should be sent to Enzo Biochem, Inc., 527 Madison Avenue, New York, New York 10022, Attention: Shahram K. Rabbani, Secretary. A return envelope which requires no postage if mailed in the United States is enclosed for your convenience.

By Order of the Board of Directors,

Shahram K. Rabbani, *Secretary*

New York, New York
November 28, 2008

ENZO BIOCHEM, INC.
527 Madison Avenue
New York, New York 10022
(212) 583-0100

PROXY STATEMENT

ANNUAL MEETING OF SHAREHOLDERS TO BE HELD ON JANUARY 22, 2009

This Proxy Statement is furnished in connection with the solicitation by the Board of Directors of Enzo Biochem, Inc., a New York corporation (the "Company"), of proxies in the enclosed form for the Annual Meeting of Shareholders to be held at The Yale Club, 50 Vanderbilt Avenue, New York, New York 10017, on January 22, 2009, at 9:00 a.m., local time (the "Annual Meeting"), and for any adjournment or adjournments thereof, for the purposes set forth in the preceding Notice of Annual Meeting of Shareholders. The persons named in the enclosed form of proxy will vote the shares for which they are appointed in accordance with the directions of the shareholders appointing them. In the absence of such directions, such shares will be voted FOR Proposals 1 and 2 listed in the preceding Notice of Annual Meeting of Shareholders and, in the best judgment of the persons named as proxies, will be voted on any other matters as may come before the Annual Meeting. Any shareholder giving a proxy has the power to revoke the same at any time before it is voted by timely filing written notice of such revocation with the Secretary of the Company, by timely submission of a duly executed proxy bearing a later date or by voting in person at the Annual Meeting. Attendance at the Annual Meeting will not in and of itself constitute revocation of a proxy. Any written notice revoking a proxy should be sent to Enzo Biochem, Inc., 527 Madison Avenue, New York, New York 10022, Attention: Shahram K. Rabbani, Secretary. A return envelope that requires no postage if mailed in the United States is enclosed for your convenience.

The expense of the solicitation of proxies for the meeting, including the cost of mailing, will be borne by the Company. In addition to mailing copies of the enclosed proxy materials to shareholders, the Company may request persons, and reimburse them for their expenses with respect thereto, who hold stock in their names or custody or in the names of nominees for others, to forward copies of such materials to those persons for whom they hold stock of the Company and to request authority for the execution of the proxies. In addition to the solicitation of proxies by mail, it is expected that some of the officers, directors and regular employees of the Company, without additional compensation, may solicit proxies on behalf of the Board of Directors by telephone, telefax and personal interview.

The principal corporate office of the Company is located at 527 Madison Avenue, New York, New York 10022. The approximate date on which this Proxy Statement and the accompanying form of proxy will first be sent or given to the Company's shareholders is on or about December 5, 2008.

VOTING SECURITIES

Only holders of record of shares of common stock, par value \$.01 per share (the "Common Stock"), of the Company as of the close of business on November 25, 2008 are entitled to notice of and to vote at the Annual Meeting (the "Record Date"). On the Record Date there were issued and outstanding 37,385,500 shares of Common Stock. Each outstanding share of Common Stock is entitled to one (1) vote upon all matters to be acted upon at the Annual Meeting. The holders of a majority of the outstanding shares of Common Stock as of the Record Date must be present in person or by proxy at the Annual Meeting to constitute a quorum for the transaction of business at the Annual Meeting.

The election of a nominee for director requires a plurality of votes (i.e., an excess of votes over those cast for an opposing candidate) in the event that more than one candidate is running for a vacancy. Shareholders may either vote for or withhold their vote for the director nominees. A properly executed proxy marked withhold with respect to the election of one or more directors will not be voted with respect to the director or directors, although it will be counted for purposes of determining whether there is a quorum. The ratification and approval of Proposal 2 will require the affirmative vote of the majority of the votes cast by holders of shares of Common Stock present in person or represented by proxy at the Annual Meeting and entitled to vote on such proposals. Abstentions and broker non-votes are not counted as votes cast on any matter to which they relate and will have no effect on the outcome of the vote with respect to any matter. A broker non-vote occurs when a broker or other nominee does not have discretionary authority and has not received instructions with respect to a particular proposal. Proxy ballots are received and tabulated by the Company's transfer agent and certified by the inspector of election.

HOUSEHOLDING OF ANNUAL MEETING MATERIALS

Some brokers and other nominee record holders may be participating in the practice of householding proxy statements. This means that only one copy of the proxy statement may have been sent to multiple shareholders in a shareholder's household. The Company will promptly deliver a separate copy of the proxy statement to any shareholder who contacts the Company's investor relations department at (212) 583-0100 or at the Company's principal corporate office at 527 Madison Avenue, New York, New York 10022 requesting such copies. If a shareholder is receiving multiple copies of the proxy statement at the shareholder's household and would like to receive a single copy of the proxy statement for a shareholder's household in the future, shareholders should contact their broker, other nominee record holder, or the Company's investor relations department to request mailing of a single copy of the proxy statement.

TABLE OF CONTENTS

	<u>PAGE</u>
<u>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT</u>	4
<u>PROPOSAL 1: ELECTION OF DIRECTOR</u>	6
<u>Nominee</u>	6
<u>Board Recommendation</u>	6
<u>DIRECTORS WHO ARE CONTINUING IN OFFICE</u>	7
<u>DIRECTORS, EXECUTIVE OFFICERS AND KEY EMPLOYEES</u>	7
<u>CORPORATE GOVERNANCE</u>	11
<u>AUDIT COMMITTEE REPORT</u>	15
<u>SECTION 16(a) BENEFICIAL OWNERSHIP REPORTING COMPLIANCE</u>	16
<u>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS</u>	16
<u>CODE OF ETHICS</u>	16
<u>COMPENSATION OF DIRECTORS</u>	17
<u>COMPENSATION OF EXECUTIVE OFFICERS</u>	18
<u>COMPENSATION COMMITTEE REPORT</u>	27
<u>COMPENSATION COMMITTEE INTERLOCKS AND INSIDER PARTICIPATION</u>	27
<u>SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS</u>	28
<u>INSURANCE FOR INDEMNIFICATION OF DIRECTORS AND OFFICERS</u>	28
<u>PROPOSAL 2: APPROVAL OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</u>	29
<u>Independent Registered Public Accounting Firm Fees</u>	29
<u>Board Recommendation</u>	30
<u>GENERAL</u>	31
<u>SHAREHOLDER PROPOSALS AND DIRECTOR NOMINATIONS TO BE PRESENTED AT THE NEXT ANNUAL MEETING</u>	32

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

Set forth below is information concerning stock ownership of all persons known by the Company to own beneficially 5% or more of the shares of Common Stock of the Company, the executive officers named under [Compensation of Directors and Executive Officers], all current directors, and all current directors and executive officers of the Company as a group based upon the number of outstanding shares of Common Stock as of the close of business on the Record Date. Except as otherwise indicated, each of the persons named has sole voting and investment power with respect to the shares shown.

Name and Address of Beneficial Owner	Amount and Nature of Beneficial Ownership (1)	Percent of Class (2)
Elazar Rabbani, Ph.D.	2,172,244 (3)	5.7%
Barry W. Weiner	1,380,766 (4)	3.7%
Shahram K. Rabbani	1,850,166 (5)	4.9%
Carl W. Balezentis, Ph.D.	12,696 (6)	*
Andrew R. Crescenzo, CPA	12,803 (7)	*
Irwin C. Gerson	72,854 (8)	*
Melvin F. Lazar, CPA	91,557 (9)	*
John B. Sias	179,343 (10)	*
Stephen B.H. Kent, Ph.D.	9,664 (11)	*
Bernard L. Kasten, MD.	6,164 (12)	*
Clearbridge Advisors, LLC and Smith Barney Fund Management LLC	4,460,546 (13)	12.00%
J. Morton Davis	3,383,030 (14)	9.10%
All directors and executive officers as a group (12 persons) (15)	6,106,557 (16)	15.68%

* Represents beneficial ownership of less than 1%.

- (1) Except as otherwise noted, all shares of Common Stock are beneficially owned and the sole investment and voting power is held by the persons named, and such persons' address is c/o Enzo Biochem, Inc., 527 Madison Avenue, New York, New York 10022.
- (2) Based upon 37,385,500 shares of Common Stock of the Company outstanding as of the close of business on the Record Date. Common Stock not outstanding but deemed beneficially owned by virtue of the right of an individual to acquire shares within 60 days from the date is treated as outstanding only when determining the amount and percentage of Common Stock owned by such individual.

Edgar Filing: ENZO BIOCHEM INC - Form DEF 14A

- (3) Includes (i) 398,752 shares of Common Stock issuable upon the exercise of options which are exercisable within 60 days from the date hereof, (ii) 3,469 shares of Common Stock held in the name of Dr. Rabbani as custodian for certain of his children, (iii) 2,168 shares of Common Stock held in the name of Dr. Rabbani's wife as custodian for certain of their children, (iv) an aggregate of 5,100 shares of Common Stock held in the name of Dr. Rabbani's children and (v) 15,000 shares of restricted Common Stock that vest within 60 days from the date hereof. Includes 5,721 shares of Common Stock held in the Company's 401(k) plan.
- (4) Includes (i) 398,752 shares of Common Stock issuable upon the exercise of options which are exercisable within 60 days from the date hereof, (ii) 3,642 shares of Common Stock that Mr. Weiner holds as custodian for certain of his children and (iii) 11,000 shares of restricted Common Stock that vest within 60 days from the date hereof. Includes 5,728 shares of Common Stock held in the Company's 401(k) plan.
- (5) Includes (i) 398,752 shares of Common Stock issuable upon the exercise of options which are exercisable within 60 days from the date hereof, (ii) 1,354 shares of Common Stock held in the name of Mr. Rabbani's son, (iii) 1,671 shares of Common Stock that Mr. Rabbani holds as custodian for certain of his nephews and (iv) 8,000 shares of restricted Common Stock that vest within 60 days from the date hereof. Includes 5,686 shares of Common Stock held in the Company's 401(k) plan.
- (6) Includes 776 shares of Common Stock held in the Company's 401(k) plan.
- (7) Includes 803 shares of Common Stock held in the Company's 401(k) plan.
- (8) Includes (i) 54,690 shares of Common Stock issuable upon the exercise of options which are exercisable within 60 days from the date hereof and (ii) 9,664 shares of restricted Common Stock vesting 60 days from the date hereof.
- (9) Includes (i) 28,644 shares of Common Stock issuable upon the exercise of options which are exercisable within 60 days from the date hereof, (ii) 26,249 shares of Common Stock owned by Mr. Lazar's wife, (iii) 11,164 shares of restricted Common Stock vesting 60 days from the date hereof and (iv) 10,500 shares in an Individual Retirement Account.
- (10) Includes (i) 64,674 shares of Common Stock issuable upon the exercise of options which are exercisable within 60 days from the date hereof and (ii) 15,828 shares of restricted Common Stock vesting 60 days from the date hereof.
- (11) Includes 9,664 shares of restricted Common Stock vesting 60 days from the date hereof.
- (12) Includes 6,164 shares of restricted Common Stock vesting 60 days from the date hereof.
- (13) The address of each entity in the group is 399 Park Avenue, New York, New York 10022. This information is based solely on a Schedule 13G filed on February 14, 2008.
- (14) Mr. Davis's address is D.H. Blair Investment Banking Corp., 44 Wall Street, New York, New York 10005. Includes (i) 33,425 shares owned directly by Mr. Davis, (ii) 1,399,345 shares owned directly by Blair Investment, (iii) 773,396 shares owned by Engex, Inc., (iv) 12,733 shares owned by an investment advisor whose principal is Mr. Davis and (v) 1,164,131 shares owned by Rosalind Davidowitz, Mr. Davis's wife. This information is based solely on a Schedule 13G filed on February 14, 2008.
- (15) The total number of directors and executive officers includes three (3) executive officers or key employees who were not named under "Security Ownership of Certain Beneficial Owners and Management."
- (16) Includes 1,565,290 shares of Common Stock issuable upon the exercise of options which are exercisable within 60 days from the date hereof, vesting of restricted stock and non-voting restricted stock units within 60 days from the date hereof.

**PROPOSAL 1
ELECTION OF DIRECTOR**

The Company has three (3) staggered classes of Directors, each of which serves for a term of three (3) years. At the Annual Meeting, the Company's Class III Director will be elected to hold office for a term of three (3) years or until his respective successors is elected and qualified. Unless otherwise instructed, the accompanying form of proxy will be voted for the election of the below-listed nominee to serve as a Class III Director. Management has no reason to believe that the nominee will not be a candidate or will be unable to serve as a director. However, in the event that the nominee should become unable or unwilling to serve as director, the form of proxy will be voted for the election of such person as shall be designated by the Class I and Class III Directors.

Effective November 8, 2006, the total cumulative length of time that any Outside Director (a member of the Board who is not an officer or employee of the Company) may serve on the Board shall be limited to a maximum of three three-year terms, whether consecutively or in total, plus any portion of an earlier three-year term that such Outside Director may have been appointed to serve.

**CLASS III DIRECTOR NOMINEE TO SERVE UNTIL
THE 2012 ANNUAL MEETING, IF ELECTED:**

Class III: Term to Expire In 2012

<u>Name</u>	<u>Age</u>	<u>Year First Became a Director</u>
Elazar Rabbani, Ph.D.	64	1976

DR. ELAZAR RABBANI (age 64) is Enzo Biochem's founder and has served as the Company's Chairman of the Board of Directors and Chief Executive Officer since its inception in 1976. Dr. Rabbani has authored numerous scientific publications in the field of molecular biology, in particular, nucleic acid labeling and detection. He is also the lead inventor of many of the Company's pioneering patents covering a wide range of technologies and products. Dr. Rabbani received his Bachelor of Arts degree from New York University in Chemistry and his Ph.D. in Biochemistry from Columbia University. He is a member of the American Society for Microbiology.

THE BOARD OF DIRECTORS OF THE COMPANY RECOMMENDS A VOTE FOR THE ELECTION OF THE ABOVE-NAMED NOMINEE. PROXIES SOLICITED BY THE BOARD OF DIRECTORS WILL BE SO VOTED UNLESS SHAREHOLDERS SPECIFY IN THEIR PROXIES A CONTRARY CHOICE.

DIRECTORS WHO ARE CONTINUING IN OFFICE:**Class I: Term to Expire In 2010**

<u>Name</u>	<u>Age</u>	<u>Year First Became a Director</u>
Shahram K. Rabbani	56	1976
Irwin C. Gerson	78	2001
Stephen B. H. Kent, Ph.D	63	2007

Class II: Term to Expire In 2011

<u>Name</u>	<u>Age</u>	<u>Year First Became a Director</u>
Barry W. Weiner	58	1977
Melvin F. Lazar, CPA	69	2002
Dr. Bernard L. Kasten	62	2008

DIRECTORS, EXECUTIVE OFFICERS AND KEY EMPLOYEES

The current directors, executive officers and key employees of the Company and its subsidiaries are identified in the table below.

<u>Name</u>	<u>Age</u>	<u>Year Became a Director or Executive Officer</u>	<u>Position</u>
Elazar Rabbani, Ph.D.	64	1976	Chairman of the Board of Directors and Chief Executive Officer
Barry W. Weiner	58	1977	President, Chief Financial Officer and Director
Shahram K. Rabbani	56	1976	Treasurer, Secretary and Director, President, Enzo Clinical Labs, Inc.
Carl W. Balezentis, Ph.D.	51	2006	President, Enzo Life Sciences, Inc.
Christine Fischette, Ph.D.	57	2008	President, Enzo Therapeutics, Inc.
Andrew R. Crescenzo, CPA	52	2006	Senior Vice President of Finance
Herbert B. Bass	60	1989	Vice President of Finance
Andrew P. Whiteley	50	2008	Vice President, Business Development and Chief Operating Officer, Enzo Life Sciences, Inc.
David C. Goldberg	51	1995	Vice President, Corporate Development
Irwin C. Gerson	78	2001	Director
Dr. Bernard L. Kasten	62	2008	Director
Stephen B. H. Kent, Ph.D.	63	2007	Director
Melvin F. Lazar, CPA	69	2002	Director
John B. Sias	81	1982 (1)	Director

(1) Director term expires January 21, 2009

Biographical Information Regarding Directors, Executive Officers and Key Employees

DR. ELAZAR RABBANI (age 64) is Enzo Biochem's founder and has served as the Company's Chairman of the Board of Directors and Chief Executive Officer since its inception in 1976. Dr. Rabbani has authored numerous scientific publications in the field of molecular biology, in particular, nucleic acid labeling and detection. He is also the lead inventor of many of the Company's pioneering patents covering a wide range of technologies and products. Dr. Rabbani received his Bachelor of Arts degree from New York University in Chemistry and his Ph.D. in Biochemistry from Columbia University. He is a member of the American Society for Microbiology. Dr. Rabbani is a nominee for re-election at the 2008 Annual Meeting.

BARRY W. WEINER (age 58) President, Chief Financial Officer and Director, is a founder of Enzo Biochem, Inc. He has served as the Company's President since 1996, and previously held the position of Executive Vice President. Before his employment with Enzo, he worked in several managerial and marketing positions at the Colgate Palmolive Company. Mr. Weiner is a Director of the New York Biotechnology Association. He received his Bachelor of Arts degree in Economics from New York University and a Master of Business Administration in Finance from Boston University.

SHAHRAM K. RABBANI (age 56) Treasurer, Secretary and Director, is a founder and has been with the Company since its inception. He is also President of Enzo Clinical Labs. Mr. Rabbani serves on the New York State Clinical Laboratory Association, a professional board. He received a Bachelor of Arts Degree in Chemistry from Adelphi University.

DR. CARL W. BALEZENTIS (age 51) President, Enzo Life Sciences, Inc. has held this position since June 2006. Before his employment with Enzo, he was CEO of Lark Technologies, Inc. from 2000 to 2004, prior to its acquisition by Genaisance Pharmaceuticals, Inc. Subsequent to the acquisition Dr. Balezentis held the positions of President of Lark Technologies, Inc., and Senior Vice President of Genaisance. From 1998 to 2000 he has held numerous executive positions in the life sciences industry at Sigma-Aldrich, Perceptive Scientific Instruments, Inc., Applied Biosystems, Inc. (now Applera) and Promega Corporation. Dr. Balezentis holds a Ph.D. in Genetics from the University of Arizona and completed a Post Doctoral Fellowship at M.D. Anderson Cancer Center in Houston, TX.

DR. CHRISTINE T. FISCHETTE (age 57) President, Enzo Therapeutics, Inc. has held this position since January 2008. Before her employment with Enzo, from 1999-2007 she was Executive Director and Head of Negotiation, Global Business Development and Licensing for various therapeutic Business Franchise Boards at Novartis Pharmaceuticals, a division of Novartis Ag. From 1987 to 1999, Dr. Fischette has held various positions at Pfizer Pharmaceuticals, NY and directed preclinical/clinical development, medical marketing, and was head of Pfizer's US commercial arm for diabetes before joining business development and licensing from 1987-1999. Prior to her work experience at Pfizer, she conducted research as Senior Scientist at Hoffmann-La Roche, Inc. and as a Post Doctoral Fellow at Rockefeller University. Dr. Fischette holds a Ph.D. in Physiology from the University of Medicine & Dentistry of New Jersey and a B.A. in Biology Education from Rutgers University.

ANDREW R. CRESCENZO, CPA (age 52) Senior Vice President of Finance for the Company has held this position since May 2006. Before joining the Company, Mr. Crescenzo was an Executive Director from 2002 to 2006 and a Senior Manager from 1997 to 2002 at Grant Thornton LLP. From 1993 to 1997 he served as Vice President and Chief Financial Officer of J. D'Addario & Co, Inc and was employed at Ernst and Young LLP from 1984 to 1993. Mr. Crescenzo is a Certified Public Accountant and received his Bachelors of Business Administration from Adelphi University.

HERBERT B. BASS (age 60) Vice President of Finance for the Company and is also Senior Vice President of Enzo Clinical Labs. Before his promotion in 1989 to Vice President of Finance, Mr. Bass served as the Corporate Controller of the Company. Mr. Bass has been with the Company since 1986. From 1977 to 1986, Mr. Bass held various positions at Danziger and Friedman, Certified Public Accountants, the latest of which was audit manager. Mr. Bass received a Bachelor of Business Administration degree in Accounting from Bernard M. Baruch College.

Edgar Filing: ENZO BIOCHEM INC - Form DEF 14A

ANDREW P. WHITELEY (age 50) Chief Operating Officer, Enzo Life Sciences and Vice President of Business Development, Enzo Biochem since May 2008. Before his employment at Enzo, Mr. Whiteley previously held the position of CEO at Vitra Biosciences (2003 to 2005) and CEO of InforMax from 2002 to 2003 which was acquired by Invitrogen. Prior to that Mr. Whiteley held various positions at Amersham Pharmacia Biotech (now part of GE Healthcare) including VP Bioinformatics and VP Sequencing Business. Mr. Whiteley graduated from Nottingham University, England with a joint honors degree in Biochemistry and Chemistry.

DAVID C. GOLDBERG (age 51) Vice President of Corporate Development for Enzo Biochem and Senior Vice President of Enzo Clinical Labs has been employed with the Company since 1985. He has held several managerial positions within Enzo Biochem. Mr. Goldberg also held management and marketing positions with DuPont-NEN and Gallard Schlesinger Industries before joining the Company. He received a Master of Science degree in Microbiology from Rutgers University and a Master of Business Administration in Finance from New York University.

IRWIN C. GERSON (age 78) has been a Director of the Company since May 2001 and is Chairman of the Compensation Committee and also serves on the Nominating/Governance Committee. From 1995 until December 1998, Mr. Gerson served as Chairman of Lowe McAdams Healthcare and prior thereto had been, since 1986, Chairman and Chief Executive Officer of William Douglas McAdams, Inc., one of the largest advertising agencies in the U.S. specializing in pharmaceutical marketing and communications to healthcare professionals. In February 2000, he was inducted into the Medical Advertising Hall of Fame. He was a director of Andrx Corporation, a NASDAQ listed company which specializes in proprietary drug delivery technologies until November 2006. From 1990-1999, he was Chairman of the Council of Overseers of the Arnold and Marie Schwartz College of Pharmacy and has served as a trustee of The Albany College of Pharmacy and Long Island University. He was elected President of the Advisory Board of Florida Atlantic University Lifelong Learning Society in October 2006. Mr. Gerson has a Bachelor of Science in Pharmacy from Fordham University and an MBA from the NYU Graduate School of Business Administration.

BERNARD L. KASTEN, MD (age 62) Dr. Kasten has been a Director of the Company since January 2008 and serves on the Audit and the Compensation Committees. He served as Director of Cleveland Biolabs, Inc. (CBLI: NASDAQ) and has been serving as Chairman of the Board since August 2006. From 1995 to 2004, Dr. Kasten served at Quest Diagnostics Incorporated where he was Chief Laboratory Officer and most recently Vice President of Medical Affairs of its MedPlus Inc. subsidiary. Dr. Kasten served as a director of SIGA Technologies from May 2003 to December 2006, and as SIGA's Chief Executive Officer from July 2004 through April 2006. Dr. Kasten currently serves as a director of GeneLink Inc. (GNLK.OTCBB) and SeraCare Life Sciences Inc. (SCRS □ Pink Sheets). Dr. Kasten is also a director of several privately held companies. Dr. Kasten is a graduate of the Ohio State University College of Medicine. His residency was served at the University of Miami, Florida and he was awarded fellowships at the National Institutes of Health Clinical Center and NCI, Bethesda, Maryland. He is a diplomat of the Board of Pathology with certification in anatomic and clinical pathology with sub-specialty certification in Medical Microbiology.

DR. STEPHEN B. H. KENT (age 63) has been a Director of the Company since January 2007 and Lead Independent Director since January 2008 and serves on the Nominating/Governance Committee. Dr. Kent is or has been a Professor of Biochemistry & Molecular Biology (2001-present), Professor of Chemistry (2002-present), and Director of the Institute for Biophysical Dynamics (2003-present) at the University of Chicago. Dr. Kent was the business founder and served as a director of CIPHERGEN Biosystems (1994-1997) and Gryphon Sciences (1994-2002). At Gryphon Sciences, Kent served as President (1997-2000), CEO (1999-2000), and Chief Scientist (1997-2001). Dr. Kent has served on the Scientific Advisory Board at Amylin Pharmaceuticals from 2005 □ present, the Board of the Center for Functional Genomics, Victoria University, New Zealand from 2004 □ present, the Scientific Advisory Board, Institute for Molecular Bioscience, The University of Queensland, Australia, from 2001 □ present, and the Scientific Advisory Board, New York Blood Center & Kimball Research Institute from 1991 □ 1997. Dr. Kent received Bachelor of Science and Master of Science degrees in his native New Zealand, and his Ph.D. from the University of California, Berkeley.

Edgar Filing: ENZO BIOCHEM INC - Form DEF 14A

MELVIN F. LAZAR, CPA (age 69) has been a Director of the Company since August 2002, the Lead Independent Director from October 2005 to January 2008, and is Chairman of the Audit Committee. Mr. Lazar was a founding partner of the public accounting firm of Lazar, Levine & Felix LLP from 1969 until October 2002. Mr. Lazar is a board member and chairman of the audit committee of Arbor Realty Trust, Inc. (ABR: NYSE). Arbor is a real estate investment trust (REIT) formed to invest in real estate related bridge and mezzanine loans, preferred equity investments and other real estate related assets. Mr. Lazar holds a Bachelor of Business Administration degree from The City College of New York (Baruch College).

JOHN B. SIAS (age 80) has been a Director of the Company since 1982 and his term expires January 22, 2009. Mr. Sias had been President and Chief Executive Officer of Chronicle Publishing Company from April 1993 to September 2000. From January 1986 until April 1993, Mr. Sias was President of ABC Network Division, Capital Cities/ABC, Inc. From 1977 until January 1986, he was the Executive Vice President, President of the Publishing Division (which includes Fairchild Publications) of Capital Cities Communications, Inc. Mr. Sias holds a Bachelor's degree in Economics from Stanford University. Mr. Sias will not be standing for election at the end of his current term.

Dr. Elazar Rabbani and Shahram K. Rabbani are brothers and Barry W. Weiner is their brother-in-law.

Irwin C. Gerson, Dr. Bernard L. Kasten, Dr. Stephen Kent, Melvin F. Lazar and John B. Sias qualify as independent directors under the criteria established by the New York Stock Exchange (NYSE).

CORPORATE GOVERNANCE

Our Board of Directors and management are committed to responsible corporate governance to ensure that the Company is managed for the long-term benefit of its shareholders. To that end, during the past year, as in prior years, the Board of Directors and management have periodically reviewed and updated, as appropriate, the Company's corporate governance policies and practices. During the past year, the Board has also continued to evaluate and, when appropriate, update the Company's corporate governance policies and practices in accordance with the requirements of the Sarbanes-Oxley Act of 2002 and the rules and listing standards issued by the Securities and Exchange Commission and the NYSE.

Corporate Governance Policies and Practices

The Company has instituted a variety of policies and practices to foster and maintain responsible corporate governance, including the following:

Corporate Governance Guidelines □ The Board of Directors adopted Corporate Governance Guidelines, which collect in one document many of the corporate governance practices and procedures that had evolved over the years. These guidelines address the duties of the Board of Directors, director qualifications and selection process, Board operations, Board committee matters and continuing education. The guidelines also provide for annual self-evaluations by the Board and its committees. The Board reviews these guidelines on an annual basis. The guidelines are available on the Company's website at www.enzo.com, and in print to any interested party that requests them.

Corporate Code of Ethics □ The Company has a Code of Ethics that applies to all of the Company's employees, officers and members of the Board. The Code of Ethics is available on the Company's website at www.enzo.com, and in print to any interested party that requests it.

Board Committee Charters □ Each of the Company's Audit, Compensation and Nominating/Governance Committees has a written charter adopted by the Company's Board of Directors that establishes practices and procedures for such committee in accordance with applicable corporate governance rules and regulations. The charters are available on the Company's website at www.enzo.com, and in print to any interested party that requests them.

Lead Independent Director Charter □ The duties of the Lead Independent Director, as set forth in the Lead Independent Director Charter, among other things, are to develop the agendas for and serve as chairman of the executive sessions of the independent directors of the Company; serve as principal liaison between the independent directors of the Company and the Chairman of the Board and between the independent directors and senior management; provide the Chairman of the Board with input as to the preparation of the agendas for Board meetings; advise the Chairman of the Board as to the quality, quantity and timeliness of the information submitted by the Company's management that is necessary or appropriate for the independent directors to effectively and responsibly perform their duties; ensure that independent directors have adequate opportunities to meet and discuss issues in executive sessions without management present; if the Chairman of the Board is unable to attend a Board of Directors meeting, act as chairman of such Board of Directors meeting; and perform such other duties as the Board of Directors shall from time to time delegate.

On October 31, 2005, the Board of Directors elected Melvin F. Lazar to serve as Lead Independent Director. Mr. Lazar served as Lead Independent Director through January 24, 2008. Dr. Stephen Kent was elected Lead Independent Director effective January 24, 2008.

The Lead Independent Director Charter is available on the Company's website at www.enzo.com, and in print to any interested party that requests it.

Director Independence

Requirements □ The Board of Directors believes that a substantial majority of its members should be independent, non-employee directors. The Board adopted the following □Director Independence Standards,□ which are consistent with criteria established by the NYSE, to assist the Board in making these independence determinations:

No Director can qualify as independent if he or she has a material relationship with the Company outside of his or her service as a Director of the Company. A Director is not independent if, within the preceding three years:

- The director was an employee of the Company.
- An immediate family member of the director was an executive officer of the Company.
- A director was affiliated with or employed by a present or former internal or external auditor of the Company.
- An immediate family member of a director was affiliated with or employed in a professional capacity by a present or former internal or external auditor of the Company.
- A director, or an immediate family member of the director, received more than \$100,000 per year in direct compensation from the Company, other than director and committee fees and pension or other forms of deferred compensation for prior services (provided such compensation is not contingent in any way on continued service).
- The director, or an immediate family member of the director, was employed as an executive officer of another company where any of the Company's executives served on that company's compensation committee of the board of directors.
- The director was an executive officer or employee, or an immediate family member of the director was an executive officer, of another company that made payments to, or received payments from, the Company for property or services in an amount which, in any single fiscal year, exceeded the greater of \$1 million or two percent (2%) of such other company's consolidated gross revenues.
- The director, or an immediate family member of the director, was an executive officer of another company that was indebted to the company, or to which the Company was indebted, where the total amount of either company's indebtedness to the other was five percent (5%) or more of the total consolidated assets of the company he or she served as an executive officer.
- The director, or an immediate family member of the director, was an officer, director or trustee of a charitable organization where the Company's annual discretionary charitable contributions to the charitable organization exceeded the greater of \$1 million or five percent (5%) of that organization's consolidated gross revenues.

The Board has reviewed all material transactions and relationships between each director, or any member of his or her immediate family, and the Company, its senior management and its independent auditors. Based on this review and in accordance with its independence standards outlined above, the Board of Directors has affirmatively determined that all of the non-employee directors are independent.

Board Nomination Policies and Procedure

Nomination Procedure □ The Nominating/Governance Committee is responsible for identifying, evaluating, and recommending candidates for election to the Board, with due consideration for recommendations made by other Board members, the CEO, shareholders, and other sources. In addition to the above criteria, the Nominating/Governance Committee also considers the appropriate balance of experience, skills, and characteristics desirable among the members of the board. The independent members of the Board review the Nominating/Governance Committee candidates and nominate candidates for election by the Company shareholders.

Directors must also possess the highest personal and professional ethics, integrity and values and be committed to representing the long-term interests of all shareholders. Board members are expected to diligently prepare for, attend and participate in all Board and applicable Committee meetings. Each Board member is expected to ensure that other existing and future commitments do not materially interfere with the member's service as a director.

The Nominating/Governance Committee also reviews whether a potential candidate will meet the Company's independence standards and any other director or committee membership requirements imposed by law, regulation or stock exchange rules.

Director candidates recommended to the Committee are subject to full Board approval and subsequent election by the shareholders. The Board of Directors is also responsible for electing directors to fill vacancies on the Board that occur due to retirement, resignation, expansion of the Board or other reasons between the Shareholders' annual meetings. The Nominating/Governance Committee may retain a recruitment firm, from time to time, to assist in identifying and evaluating director candidates. When a firm is used, the Committee provides specified criteria for director candidates, tailored to the needs of the Board at that time, and pays the firm a fee for these services. Suggestions for director candidates are also received from board members and management and may be solicited from professional associations as well.

Board Committees

All members of each of the Company's three standing committees □ the Audit, Compensation, and Nominating/Governance □ are required to be independent in accordance with NYSE criteria. See below for a description of the responsibilities of the Board's standing committees.

Executive Sessions of Non-Management Directors

The Board and the Audit, Compensation and Nominating/Governance Committees periodically hold meetings of only the independent directors or Committee members without management present.

Board Access to Independent Advisors

The Board as a whole, and each of the Board committees separately, has authority to retain and terminate such independent consultants, counselors or advisors to the Board as each shall deem necessary or appropriate.

Communications with Board of Directors

Direct Communications □ Any interested party desiring to communicate with the Board of Directors or with any director regarding the Company may write to the Board or the director, c/o Shahram K. Rabbani, Office of the Secretary, Enzo Biochem, Inc., 527 Madison Avenue, New York New York 10022. The Office of the Secretary will forward all such communications to the director(s). Interested parties may also submit an email by filling out the email form on the Company's website at www.enzo.com. Moreover, any interested party may contact the non-management directors of the Board and/or the presiding (or lead) director.

Annual Meeting □ The Company encourages its outside directors to attend the annual meeting of shareholders each year. Messrs. Gerson, Kent, Lazar, Sias and Dr. Kasten attended the Annual Meeting of Shareholders held in January 2008.

Meetings of the Board of Directors and its Committees

During the fiscal year ended July 31, 2008, there were seven formal meetings of the Board of Directors, several actions by unanimous consent and several informal meetings. None of the Directors attended less than 75% of the meetings. Currently, the Board of Directors has a Nominating/Governance Committee, an Audit Committee and a Compensation Committee. The Nominating/Governance Committee had one formal meetings, the Audit Committee had four formal meetings and the Compensation Committee had five formal meetings.

The Audit Committee was established by and among the Board of Directors for the purpose of overseeing the accounting and financial reporting processes of the Company and audits of the financial statements of the Company in accordance with Section 3(a)(58)(A) of the Securities Exchange Act of 1934, as amended, The Audit Committee is authorized to review proposals of the Company's auditors regarding the annual audit, recommend the engagement or discharge of the auditors, review recommendations of such auditors concerning accounting principles and the adequacy of internal controls and accounting procedures and practices, review the scope of the annual audit, approve or disapprove each professional service or type of service other than standard auditing services to be provided by the auditors, and review and discuss the audited financial statements with the auditors. The current members of the Audit Committee are Messrs. Lazar, Sias and Dr. Kasten. Mr. Lazar is the Chairman. The Board of Directors has determined that each of the Audit Committee members are independent, as defined in the NYSE's listing standards and as defined in Item 7(d)(3)(iv) of Schedule 14A under the Securities and Exchange Act of 1934 The Board of Directors has further determined that Messrs. Sias and Lazar are each □audit committee financial experts□ as such term is defined under Item 401(h)(2) of Regulation S-K.

The Compensation Committee has the power and authority to (i) establish a general compensation policy for the officers and employees of the Corporation, including to establish and at least annually review officers' salaries and levels of officers' participation in the benefit plans of the Corporation, (ii) prepare any reports that may be required by the regulations of the Securities and Exchange Commission or otherwise relating to officer compensation, (iii) approve any increases in directors' fees, (iv) grant stock options and/or other equity instruments (v) exercise all other powers of the Board of Directors with respect to matters involving the compensation of employees and the employee benefits of the Corporation as shall be delegated by the Board of Directors to the Compensation Committee. The current members of the Compensation Committee are Messrs. Gerson, Lazar and Dr. Kasten. Mr. Gerson is the Chairman.

The Nominating/Governance Committee has the power to recommend to the Board of Directors prior to each annual meeting of the shareholders of the Corporation: (i) the appropriate size and composition of the Board of Directors; and (ii) nominees: (1) for election to the Board of Directors for whom the Corporation should solicit proxies; (2) to serve as proxies in connection with the annual shareholders' meeting; and (3) for election to all committees of the Board of Directors other than the Nominating/Governance Committee. The Nominating/Governance Committee will consider nominations from the shareholders, provided that they are made in accordance with the Company's By-laws. The current members of the Nominating/Governance Committee are Dr. Kent and Mssrs. Gerson and Sias. Dr. Kent is the Chairman.

Audit Committee Report

In connection with the preparation and filing of the Company's Annual Report on Form 10-K for the year ended July 31, 2008:

(1) The Audit Committee reviewed and discussed the audited financial statements and related footnotes with management and the independent registered public accounting firm. Management represented to the Audit Committee that the Company's financial statements were prepared in accordance with generally accepted accounting principles.

(2) The Audit Committee discussed with the independent registered public accountants matters required to be discussed under Statement on Auditing Standards No. 61, as may be modified or supplemented;

(3) The Audit Committee reviewed the written disclosures and the letter from the independent registered public accountants required by the applicable requirements of the Public Company Accounting Oversight Board, as may be modified or supplemented, regarding the independent registered public accounting firm's communication with the Audit Committee concerning independence and discussed with Ernst and Young their independence.

(4) The Audit Committee discussed with the Company's independent registered public accountants the overall scope and plans for its audit. The Audit Committee met with the independent registered public accountants, with and without management present, to discuss the results of their examinations, their evaluations of the Company's internal controls, and the overall quality (and not merely the acceptability) of the Company's accounting principles and financial reporting, the reasonableness of significant estimates and judgments, and the disclosures in the Company's financial statements, including the disclosures relating to critical accounting policies. The Audit Committee held four formal meetings during the fiscal year ended July 31, 2008; and

(5) Based on the review and discussions referred to above, the Audit Committee recommended to the Board of Directors that the audited financial statements be included in the Company's Annual Report on Form 10-K for the fiscal year ended July 31, 2008. We also selected Ernst and Young LLP as the independent registered public accounting firm for fiscal 2009. The Board is recommending that shareholders ratify that selection at the Annual Meeting.

Submitted by the members of the Audit Committee

Melvin F. Lazar, CPA
Dr. Bernard L. Kasten
John B. Sias

Section 16(a) Beneficial Ownership Reporting Compliance

Section 16(a) of the Securities Exchange Act of 1934, as amended, requires the Company's executive officers, directors and persons who beneficially own more than 10% of a registered class of the Company's equity securities (collectively, "Reporting Persons") to file with the Securities and Exchange Commission initial reports of ownership and reports of changes in ownership of common stock and other equity securities of the Company. Such executive officers, directors and greater than 10% beneficial owners are required by Securities and Exchange Commission regulation to furnish the Company with copies of all Section 16(a) forms filed by such reporting persons.

Based solely on the Company's review of such forms furnished to the Company and written representations from certain reporting persons, the Company believes that the Reporting Persons have complied with all applicable filing requirements during the fiscal year ended July 31, 2008.

Certain Relationships and Related Transactions

Enzo Clinical Labs, Inc. ("Enzo Lab"), a subsidiary of the Company, leases a facility located in Farmingdale, New York from Pari Management Corporation ("Pari"). Pari is owned equally by Elazar Rabbani, Ph.D., Shahram Rabbani and Barry Weiner and his wife, who are the officers and directors of Pari. The lease originally commenced on December 20, 1989, but was amended and extended in March 2005 and now terminates on March 31, 2017. During fiscal year ended July 31, 2008, Enzo Lab paid approximately \$1,395,000 (including approximately \$150,000 in real estate taxes) to Pari with respect to such facility and future payments are subject to cost of living adjustments. The non-interested members of the Board of Directors have reviewed and approved this transaction in accordance with the Company's procedures for reviewed related party transactions. The Company, which has guaranteed Enzo Lab's obligations to Pari under the lease, believes that the existing lease terms are as favorable to the Company as would be available from an unaffiliated party.

Code of Ethics

The Company has adopted a Code of Ethics (as such term is defined in Item 406 of Regulation S-K). The Code of Ethics is available on the Company's website at www.enzo.com, and in print to any shareholder that requests it. The Code of Ethics applies to the Company's employees, officers and members of the board. The Code of Ethics has been designed to deter wrongdoing and to promote:

- (1) Honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between personal and professional relationships;
- (2) Full, fair, accurate, timely, and understandable disclosure in reports and documents that the Company files with, or submits to, the Securities and Exchange Commission and in other public communications made by the Company;
- (3) Compliance with applicable governmental laws, rules and regulations;
- (4) The prompt internal reporting or violations of the Code of Ethics to an appropriate person or persons identified in the Code of Ethics; and
- (5) Accountability for adherence to the Code of Ethics.

COMPENSATION OF DIRECTORS

Effective January 1, 2008, the Lead Independent Director receives an annual director's fee of \$25,000 and each other person who serves as a director and who is not otherwise an officer or an employee (such director being classified as an "Outside Director") of the Company, receives an annual director's fee of \$30,000. Additionally, each Outside Director who serves on a committee of the Board of Directors receives an annual fee of \$7,500. In addition to the annual director fee, the Chairman of the Audit Committee receives an annual additional fee of \$20,000 and the Chairman of the Compensation Committee and the Chairman of the Nominating/Governance Committee each receives an additional annual fee of \$10,000. Each of the other Outside Directors will receive restricted stock units immediately following the Annual Meeting, provided such person is a director of the Company at such time. The number of restricted stock units that the Outside Directors will receive grants equal to \$125,000 per year. Each of the restricted stock units referred to above shall be subject to a two-year vesting period; provided that at the time any non-employee director ceases to be a director of the Company (other than due to such director's resignation), such non-employee director's restricted stock units shall become fully vested at such time. The Company reimburses directors for their travel and related expenses in connection with attending meetings of the Board of Directors and Board-related activities.

The Board determined that the changes set forth above provide non-executive director compensation more in line with those received by non-executive directors in its peer group.

Through December 31, 2007, the Lead Independent Director received an annual director's fee of \$50,000 and each other person who serves as a director and who is not otherwise an officer or an employee (such director being classified as an "Outside Director") of the Company, received an annual director's fee of \$20,000. For each meeting of the Board of Directors attended in person or by telephone, the Lead Independent Director and all other Outside Directors received a fee of \$2,000. Additionally, each Outside Director who served on a committee of the Board of Directors received a fee of \$1,000 for each meeting of the committee attended in person or by telephone. In addition to the \$1,000 per committee meeting fee, the Chairman of the Audit Committee received an additional fee of \$1,000 for each meeting of the Audit Committee attended in person or by telephone, the Lead Independent Director received an additional fee of \$500 for each meeting of any Board committee attended in person or by telephone, and the Chairman of the Compensation Committee and the Chairman of the Nominating/Governance Committee each received an additional fee of \$500 for each meeting of the committee attended in person or by telephone. The Lead Independent Director received restricted stock units immediately following the Annual Meeting, provided such person was a director of the Company at such time. Each of the other Outside Directors received restricted stock units immediately following the Annual Meeting, provided such person was a director of the Company at such time. The number of restricted stock units that the Lead Independent Director and each of the Outside Directors received was determined on an annual basis by the Compensation Committee. Each of the restricted stock units referred to above was subject to a two-year vesting period; provided that at the time any non-employee director ceases to be a director of the Company (other than due to such director's resignation), such non-employee director's restricted stock units became fully vested at such time.

DIRECTOR COMPENSATION TABLE

The following table sets forth the information concerning compensation earned during our fiscal year ended July 31, 2008 by all non-employee directors:

Name	Fees Earned or Paid in Cash (\$)	Stock Awards (\$ (2))	Option Awards (\$)	Change in Pension Value and Non-Qualified	All Other Compensation (\$)	Total (\$)
				Deferred Compensation Earnings (\$)		
John J. Delucca (1) <i>Director</i>	\$26,000	\$58,071				\$84,071
Irwin C. Gerson <i>Director</i>	\$61,500	\$103,287				\$164,787
Barnard Kasten (1) <i>Director</i>	\$30,000	\$36,460				\$66,460
Stephen P. H. Kent <i>Director</i>	\$64,750	\$119,640				\$184,390
Melvin F. Lazar, CPA <i>Director</i>	\$94,500	\$140,093				\$234,593
John B. Sias <i>Director</i>	\$51,000	\$134,538				\$185,538

(1) Represents partial year as director.

(2) Each independent director, serving after the annual meeting in January 2008, was awarded 12,328 restricted stock units in fiscal 2008. The amounts reflect the dollar amount recognized for financial statement reporting purposes for the fiscal year ended July 31, 2008, in accordance with FAS 123(R) for awards pursuant to the Company's 2005 Plan for awards granted in and prior to fiscal 2008.

COMPENSATION OF EXECUTIVE OFFICERS**Compensation Discussion and Analysis**

The Compensation Committee of our Board of Directors oversees our executive compensation program. In this role, the Compensation Committee reviews and approves all compensation decisions relating to our named executive officers. The Compensation Committee also reviews and approves all equity awards for all employees.

The Company strives to apply a uniform philosophy to compensation for all of its employees. This philosophy is based on the premise that the achievements of the Company result from the combined and coordinated efforts of all employees working toward common objectives.

Objectives and Philosophy of Our Executive Compensation Program

The primary objectives of the Compensation Committee with respect to executive compensation are to:

- align executive compensation with comparable companies in our industry sectors to attract, retain and motivate the best possible executive talent;
- ensure that executive compensation is aligned with our corporate business objectives and performance;

- promote the achievement of key strategic and financial performance objectives by linking cash and equity incentives; and
- align executives' incentives with the creation of long-term stockholder value.

To achieve these objectives, the Compensation Committee evaluates senior management with input from our CEO, with the goal of setting compensation at levels the Compensation Committee believes are competitive with those of other companies in our industry that compete with us for executive talent. The Compensation Committee also conducts an annual evaluation of the CEO in addition to senior management evaluations. As part of these evaluations, our Compensation Committee considers key strategic, financial and operational objectives, including but not limited to: award of new patents, intellectual property protection, advancement of strategic alliances, collaborations, M&A activity, licensing, clinical trial progress, new product introductions, provider contracts, investor relations, corporate governance, and our financial and operational performance, as measured by the respective value drivers in each of the operating segments.

We may also award long term incentive compensation in the form of restricted stock awards that vest over time. We believe this practice helps to retain our executives and aligns their interests with those of our stockholders by allowing them to participate in the longer term success of our Company as reflected in stock price appreciation.

In making compensation decisions, the Compensation Committee compares our executive compensation against a peer group of publicly traded companies which they believe have business life cycles, revenues, market capitalizations, products, research and development investment levels and/or number/capabilities of employees that are roughly comparable to ours and against which the Compensation Committee believes we compete for executive talent. In 2005, the Compensation Committee retained James F. Reda & Associates LLC, (Consultant) an independent compensation consultant. The Company's senior management, with the assistance of the Consultant, compiled a list of peer companies. The Consultant then analyzed the executive compensation programs of these companies and issued a report to the Compensation Committee. In 2007, the Consultant modified the peer company list to better reflect changes at the Company, with respect to operating segment significance, changes within the industries that the Company operates and changes among companies included in the peer group.

The companies included in the peer group, as updated, surveyed by the Consultants in 2007:

- Cryolife, Inc.
- Dialysis Corp. of America
- Idenix Pharmaceuticals, Inc.
- Incyte, Corp.
- Integred America, Inc.
- Intermune, Inc.
- Isis Pharmaceuticals, Inc.
- Lexicon Pharmaceuticals, Inc.
- Monogram Biosciences, Inc.
- Myraid Genetics, Inc.
- Nighthawk Radiology Holdings, Inc.
- Omrix Biopharmaceuticals, Inc.
- Orchid Cellmark, Inc.
- Paincare Holdings, Inc.
- Progenics Pharmaceuticals
- Supergen, Inc
- Trimeris, Inc.
- United Therapeutics Corp.
- Visicu, Inc.

We compete with many other companies for executive personnel. The Compensation Committee generally targets total compensation for executives at the 50th percentile of total compensation paid to similarly situated executives of the companies in the peer group.

The Compensation Committee may adjust compensation levels, upon consideration of the relevant drivers relating to the life sciences, clinical diagnostics or therapeutics industries we operate in, with respect to an executive's individual experience and performance level, and our overall Company performance.

The Compensation Committee met five times in fiscal 2008 in order to review and approve our compensation for named executives and non-employee directors, review candidates presented by senior management for key positions, approve equity awards for all employees and review with our Consultant the peer group information. The results of the Compensation Committee activities were reported to the Board of Directors.

Components of our Executive Compensation Program

The primary elements of our executive compensation program are:

- base salary;
- cash bonus;
- equity awards;
- benefits and other compensation; and
- severance and change-of-control benefits.

Base Salary

Base salary levels recognize the experience, skills, knowledge and responsibilities of each executive's position within the Company.

Exclusive of the base salaries that are contractual, base salaries are reviewed annually by the Compensation Committee, and may be adjusted from time to time to realign salaries with market levels and among our peer group after taking into account individual responsibilities, performance, and experience and for cost of living. Base salaries also may be increased for merit reasons, based on the executive's success in meeting or exceeding individual performance objectives, promoting our core values and demonstrating leadership abilities.

The base salaries of the three founders: our Chairman of the Board, Chief Executive Officer and Director; our President, Chief Financial Officer and Director; and our Treasurer, Secretary, President of Enzo Clinical Labs and Director, are contractual and in accordance with executed employment agreements. Pursuant to the terms of their respective Employment Agreements, Messrs. Weiner and Rabbani and Dr. Rabbani are currently compensated for the calendar year 2008 at a base annual salary of \$460,131, \$460,131 and \$518,750, respectively. Base salaries in calendar year 2008 increased by 3.8% for the executives.

The base salaries for the other two named executives, Dr. Carl W. Balezentis and Andrew R. Crescenzo were based on their initial one year employment agreements in fiscal 2006. Dr. Balezentis and Mr. Crescenzo are currently compensated for the calendar year 2008 at the base salary of \$235,000 and \$225,000, respectively. Their base salaries increased 9% in calendar year 2008, reflective of cost of living, merit and alignment with market levels.

Annual Cash Bonus

The Compensation Committee approves discretionary cash bonuses for certain employees, including our named executive officers.

The Compensation Committee awarded Dr. Rabbani a \$375,000 cash bonus, which represented 73% of his base salary at such date. The Compensation Committee recognized Dr. Rabbani's broad contributions in the areas of his role as Chairman of the Board, oversight of and increases to our technology platform and scientific product development, recruitment of new members of the executive and scientific management and strategy for business development, including negotiating licensing and collaboration arrangements and M&A activities.

The Compensation Committee awarded Mr. Weiner a \$250,000 cash bonus, which represented 55% of his base salary at such date. The Compensation Committee recognized Mr. Weiner's contributions in, strategic planning, financial management, including our Company's financial position and liquidity, M&A activity, corporate governance, communication efforts with our stockholders, investors and outside analysts, oversight of the finance group and compliance with the Company's Section 404 Sarbanes Oxley requirements, role in recruitment of new management personnel and divisional management and leadership role among the divisional executives.

The Compensation Committee awarded Mr. Rabbani a \$225,000 cash bonus, which represented 50% of his base salary at such date. The Compensation Committee recognized Mr. Rabbani's contributions relating to financial improvements at the Clinical Lab, in particular in the billing and collection area, expansion of the managed care contracts, on-going identification and evaluation of acquisition targets, representation of Clinical Lab at industry organizations.

The discretionary cash bonuses for Dr. Balezentis and Mr. Crescenzo were \$60,000 and \$50,000, respectively, as recommended by our CEO to the Compensation Committee, based on various objectives, expanded below, specific to their positions.

The Compensation Committee reviewed the recommendation from our CEO with respect to Dr. Balezentis's performance in meeting objectives set forth to grow Enzo Life Sciences through organic growth, strategic alliances, licensing or through acquisitions, increase the management team to meet the requirements of the subsidiary and his role in leadership among the division's management.

The Compensation Committee reviewed the recommendation from our CEO with respect to Mr. Crescenzo's performance in meeting objectives set forth to enhance financial reporting to the Board and the Audit Committee, manage financial aspects of M&A transactions, implement internal controls and Section 404 requirements, and role in leadership among our finance group.

Restricted Stock Awards

At its sole discretion, the Compensation Committee awards restricted stock as the primary vehicle for long-term incentives to our executives, including our named executive officers. Since August 1, 2005, we have not issued any stock options to any employees, including the named executives.

We believe that equity awards provide our executives with a strong link to our long-term performance, create an ownership culture, and help to align the interests of our named executive officers and our stockholders. Equity awards are intended as both a reward for contributing to the long-term success of our Company and an incentive for future performance.

Restricted stock awards vest ratably over a 2 to 4 year period with 50% to 25% of the award vesting 12 months after the named executive officer's start date or the annual anniversary of the award grant and the remainder of the awards vesting annually over the remaining period. The vesting feature of our equity grants is intended to further our goal of executive retention by providing an incentive to our named executive officers to remain in our employ during the vesting period.

In determining the size of equity awards to our executives, our Compensation Committee considers comparable equity awards of executives in our compensation peer group, our Company-level performance, the applicable executive's performance, the amount of equity previously awarded to the executive, the vesting schedule of such previous awards and the recommendations of management and its independent Consultant to the Compensation Committee.

Edgar Filing: ENZO BIOCHEM INC - Form DEF 14A

Equity awards of restricted stock are discretionary, and may be granted annually in conjunction with the review of an executive's individual performance. The Compensation Committee reviews all components of the executive's compensation, including the allocation between cash and equity, when determining annual equity awards to ensure that an executive's total compensation conforms to our overall philosophy and objectives.

In December 2007, Dr. Rabbani and Messrs. Weiner and Rabbani were awarded 15,000, 12,000, and 9,000 shares of restricted stock, respectively, as a component of their total compensation package.

In December 2007, Dr. Balezentis and Mr. Crescenzo were awarded 7,500 and 6,000 shares of restricted stock, respectively, as a component of their total compensation package.

The Compensation Committee has a policy not to approve annual equity awards to any employees, including named executive officers, at a time when our Company is in possession of material non-public information. We do not engage in timing of restricted stock awards to named executive officers in coordination with the release of material non-public information.

Summary Compensation Table

The following table sets forth summary information concerning compensation awarded to, paid to or earned by each of our named Executive Officers for all services rendered for each of the fiscal years ended July 31, 2008 and 2007:

Name and Principal Position (a)	Year (\$) (b)	Salary (\$) (c)	Bonus (1) (\$) (d)	Stock Awards (2) (\$) (e)	Option Awards (f)	Non-Equity Incentive Plan Compensation (g)	Change in Pension Value and Nonqualified Deferred Compensation Earnings (\$) (h)	All Other Compensation (i)
Elazar Rabbani, Ph.D <i>Chairman of the Board of Directors, and Chief Executive Officer</i>	2008	\$510,817	\$375,000	\$76,950				\$
	2007	\$485,006	\$350,000	\$65,669				\$
Barry W. Weiner <i>President and Chief Financial Officer</i>	2008	\$453,094	\$250,000	\$51,300				\$
	2007	\$434,932	\$225,000	\$43,779				\$
Shahram K. Rabbani <i>Treasurer, Secretary President, Enzo Clinical Labs</i>	2008	\$453,094	\$225,000	\$35,910				\$
	2007	\$436,334	\$200,000	\$30,645				\$
Carl W. Balezentis, Ph.D <i>President, Enzo Life Sciences</i>	2008	\$226,537	\$ 65,000	\$11,914				\$
	2007	\$215,000	\$ 40,000	\$19,088				\$
Andrew R. Crescenzo <i>Senior Vice President of Finance</i>	2008	\$216,538	\$ 50,000	\$19,040				\$
	2007	\$205,000	\$ 35,000	\$31,160				\$

- 1) Represents the discretionary cash bonus awards paid in January 2008 and 2007, respectively - see Compensation Discussion & Analysis.
- 2) Represents value of vested restricted stock awards.
- 3) See the All Other Compensation Table for additional information.

Grants of Equity Awards in Fiscal 2008

During the fiscal year ended July 31, 2008, the Compensation Committee approved the following equity awards to our named executive officers:

Name	Grant Date	Estimated Future Payouts Under Non-Equity Incentive Plan Awards			Estimated Future Payouts Under Equity Incentive Plan Awards			All Other Stock Awards:	All Other Option Awards:
		Threshold	Target	Maximum	Threshold	Target	Maximum	Number of Shares of Stock or Units (#)	Number of Securities Underlying Options (#)
		(c)	(d)	(e)	(f)	(g)	(h)	(i)	(j)
Dr. Elazar Rabbani	12/7/2007							15,000	
Barry W. Weiner	12/7/2007							12,000	
Shahram K. Rabbani	12/7/2007							9,000	
Dr. Carl W. Balezentis	12/7/2007							7,500	
Andrew R. Crescenzo	12/7/2007							6,000	

Outstanding Equity Awards at Fiscal Year End □ July 31, 2008

The following table sets forth summary information regarding the outstanding equity awards made to our Named Executive Officers at July 31, 2008.

Name	Equity Incentive Plan Awards:			Option Exercise Price (\$)	Option Expiration Date	Number of Shares or Units of Stock That Have Not Vested (#)	Market Value of Shares or Units of Stock That Have Not Vested
	Number of Securities Underlying Unexercised Option (#)	Number of Securities Underlying Unexercised Option (#)	Number of Securities Underlying Unearned Options (#)				
	(b)	(c)	(d)				
Dr. Elazar Rabbani	60,775			\$5.45	10/1/2008	22,500	\$319,725
	72,930			\$8.33	6/30/2009		
	86,822			\$12.05	3/22/2011		
	110,250			\$12.24	1/25/2013		
	78,750			\$17.45	3/8/2014		
	50,000			\$17.66	1/21/2015		
Barry W. Weiner	60,775			\$5.45	10/1/2008	17,000	\$241,570
	72,930			\$8.33	6/30/2009		
	86,822			\$12.05	3/22/2011		
	110,250			\$12.24	1/25/2013		
	78,750			\$17.45	3/8/2014		
	50,000			\$17.66	1/21/2015		
Shahram K. Rabbani							

Edgar Filing: ENZO BIOCHEM INC - Form DEF 14A

60,775	\$5.45	10/1/2008	12,500	\$177,625
72,930	\$8.33	6/30/2009		
86,822	\$12.05	3/22/2011		
110,250	\$12.24	1/25/2013		
78,750	\$17.45	3/8/2014		
50,000	\$17.66	1/21/2015		
Dr. Carl W. Balezentis			10,000	\$142,100
Andrew R. Crescenzo			8,000	\$113,680

- 1) The amount listed in this column does not include accrued amounts such as accrued salary or vacation.
- 2) Equity will vest only as involuntary termination attributed to a Change in Control.

Options Exercised and Stock Vested

The following table sets forth the options exercised and stock vested during the fiscal year ended July 31, 2008.

Name (a)	Option Awards		Stock Awards	
	Number of Shares Acquired On Exercise (#)	Value Realized On Exercise (\$)	Number Of Shares Acquired On Vesting (#)	Value Realized On Vesting (\$)
Dr. Elazar Rabbani	63,814	\$206,821	7,500	\$76,950
Barry W. Weiner	63,814	\$206,821	5,000	\$51,300
Shahram K. Rabbani	63,814	\$206,821	3,500	\$35,910
Dr. Carl W. Balezentis			1,250	\$11,914
Andrew R. Crescenzo			2,000	\$19,040

Employment Agreements

Each of Mr. Barry Weiner, Mr. Shahram Rabbani and Dr. Elazar Rabbani (the "Executives"), collectively, the founders of our Company, are parties to an employment agreements effective May 4, 1994, as amended as of July 13, 2000 (the "Employment Agreement(s)"), with the Company. Each Executive will also receive an annual bonus, the amount of which shall be determined by the Board of Directors in its discretion. Each Employment Agreement provides that, in the event of termination of employment by the Executive for "good reason," or a termination of employment by the Company without "cause," change in control or non renewal, as such terms are defined in the Employment Agreement, each Executive shall be entitled to receive: (a) a lump sum in an amount equal to three years of the Executive's base annual salary; (b) a lump sum in an amount equal to the annual bonus paid by the Company to the Executive for the last fiscal year of the Company ending prior to the date of termination multiplied by three; (c) insurance coverage for the Executive and his dependents, at the same level and at the same charges to the Executive as immediately prior to his termination, for a period of three (3) years following his termination from the Company; (d) all accrued obligations, as defined therein; and (e) with respect to each incentive pay plan (other than stock option or other equity plans) of the Company in which the Executive participated at the time of termination, an amount equal to the amount the Executive would have earned if he had continued employment for three additional years. If the Executive is terminated by reason of his disability, he shall be entitled to receive, for three years after such termination, his base annual salary less any amounts received under a long term disability plan. If the Executive is terminated by reason of his death, his legal representatives shall receive the balance of any remuneration due him under the terms of his Employment Agreement. The term of each of the Executive's Employment Agreement currently expires on May 4, 2010, which term automatically renews for successive two year periods, if notice to the Company is not given by either party within 180 days of the end of such successive term.

On April 16, 2006 and May 1, 2006, Mr. Crescenzo and Dr. Balezentis, respectively entered into one year employment agreements in connection with their initial employment. These agreements were not renewed by the Company and the executives continued their employment with the Company "at will". Beyond the initial year of their employment, both named executives have certain severance arrangements and or change in control provisions which are deemed customary practice for the respective positions.

Benefits and All Other Compensation

We maintain broad-based benefits that are provided to all employees, including health and dental insurance, group life insurance and a 401(K) plan. Named executive officers are eligible to participate in our employee benefit plans. The annual Company match for our named executive officers is up to 10,250 or limited to 50% of the maximum contribution by the named executive.

Certain of our named executive officers may be entitled to benefits that are not otherwise available to all of our employees, including life insurance and disability benefits. We do not provide pension arrangements, post-retirement health coverage to our named executive officers or our employees. Our health and insurance plans are substantially the same among all management level and sales personnel at the Company. On July 31, 2008, the Company terminated the Split Dollar life insurance arrangements with the three founders and their related trusts. In connection with the terminations of the Split Dollar life insurance arrangements, the executives will be provided the annual benefit attributed to the life insurance in their future total compensation arrangement.

In particular circumstances, we may provide relocation allowances when executives first join us. The purpose of this program is to attract talented executives outside our geographic area. Certain named executives are provided use of a Company owned vehicle for business and personal use or provided a car allowance.

All Other Compensation in Fiscal 2008 and 2007

The following table contains information regarding each component of "All Other Compensation" in the Summary Compensation Table of our Named Executives for fiscal years ended July 31, 2008 and 2007.

Name	Year	401(K) (\$ (1))	Life	Disability	Personal	Relocation (\$ (4))	Total
			Insurance (\$ (2))	Insurance (\$ (3))	Use of Auto (\$ (3))		All Other Compensation (\$)
Dr. Elazar Rabbani	2008	\$10,250	\$47,806	\$3,200	\$13,800		\$75,056
	2007	\$10,000	\$47,030	\$3,200	\$13,708		\$73,938
Barry W. Weiner	2008	\$10,250	\$39,131	\$2,500	\$14,800		\$66,681
	2007	\$10,000	\$38,017	\$2,500	\$14,800		\$65,317
Shahram K. Rabbani	2008	\$10,250	\$14,100	\$2,400	\$6,090		\$32,840
	2007	\$10,000	\$14,100	\$2,400	\$14,290		\$40,790
Dr. Carl W. Balezentis	2008	\$9,890			\$3,900		\$13,790
	2007					\$20,134	\$20,134
Andrew R. Crescenzo	2008	\$10,225			\$3,900		\$14,125
	2007						

- 1) Represents Company match under our 401(K) plan.
- 2) Represents economic value of split dollar premiums and premiums of term policies of which the Named Executive or other party is the beneficiary. The split dollar arrangements were terminated on July 31, 2008.
- 3) Represents the personal use of company provided auto or auto allowance paid.
- 4) Represents relocation costs paid in connection with an employment agreement.

Severance and Change-of-Control Benefits

Pursuant to Employment Agreements entered into with Dr. Rabbani, Messrs. Weiner, Rabbani, and Crescenzo and Dr. Balezentis, these executives are entitled to specified benefits in the event of the termination of their employment under specified circumstances, including termination following a change of ownership or control of our Company. We have provided more information about these benefits, along with estimates of their value under various circumstances within the below table entitled.

Edgar Filing: ENZO BIOCHEM INC - Form DEF 14A

Based on market trends, we believe these benefits help us compete for executive talent. We believe our severance and change of control benefits are in line with severance packages offered to executives by the companies identified in our peer group.

Our practice in the case of change of control benefits has been structured to trigger only in the event of a termination of the executive without cause or by the executive for good reason during a specified period before or after the change of control. A change of control in of itself would not trigger most severance benefits.

POTENTIAL PAYMENTS UPON TERMINATION OR CHANGE OF CONTROL

The following table contains information regarding each component of Potential Payments Upon Termination or Change in Control Compensation Table of our Named Executives as of July 31, 2008.

Name and Principal Position	Acceleration of Vesting (1)	Severance Pay (2)	Continuation of Benefits	Tax Gross-Up	Total
Elazar Rabbani, Ph.D					
Termination without cause or by Executive for Good Reason	\$319,725	\$2,681,250	\$254,407		\$3,255,382
Change in control transaction without termination					
Change in control transaction with termination	\$319,725	\$2,681,250	\$254,407	\$1,237,705	\$4,493,087
Barry W. Weiner					
Termination without cause or by Executive for Good Reason	\$241,570	\$2,055,393	\$225,205		\$2,522,168
Change in control transaction without termination					
Change in control transaction with termination	\$241,570	\$2,055,393	\$225,205	\$905,650	\$3,427,818
Shahram K. Rabbani					
Termination without cause or by Executive for Good Reason	\$177,625	\$2,130,393	\$147,714		\$2,455,732
Change in control transaction without termination					
Change in control transaction with termination	\$177,625	\$2,130,393	\$147,714	\$822,294	\$3,278,026
Carl W. Balezentis, Ph.D					
Termination without cause or by Executive for Good Reason		\$117,500			\$117,500
Change in control transaction without termination					
Change in control transaction with termination	\$142,100	\$117,500			\$259,600
Andrew R. Crescenzo					
Termination without cause or by Executive for Good Reason	\$28,420	\$75,000			\$103,420
Change in control transaction without termination					
Change in control transaction with termination	\$113,680	\$75,000			\$188,680

1) The amount listed in this column does not include accrued amounts such as accrued salary or vacation.

2) Equity will vest only as involuntary termination attributed to a Change in Control.

Tax and Accounting Considerations

The federal tax laws impose requirements in order for compensation payable to the CEO and certain executive officers to be fully deductible. The Company believes it has taken appropriate actions to maximize its income tax deduction. IRC Section 162(m) generally precludes a public corporation from taking a deduction for compensation in excess of \$1,000,000 for its CEO or any of its three other highest-paid executive officers (other than the CEO or Chief Financial Officer), unless certain specific and detailed criteria are satisfied.

Annually, the Company reviews all compensation programs and payments to determine the tax impact on the Company as well as on the executive officers. In addition, the Company reviews the impact of its programs against other considerations, such as accounting impact, stockholder alignment, market competitiveness, effectiveness and perceived value to employees. Because many different factors influence a well-rounded, comprehensive executive compensation program, some compensation may not be deductible under IRC Section 162(m). The Company will continue to monitor developments and assess alternatives for preserving the deductibility of compensation payments and benefits to the extent reasonably practicable, consistent with its compensation policies and as determined to be in the best interests of the Company and its stockholders.

Compensation Committee Report

The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis in this proxy report with management. Based on its review and discussion with management, the Compensation Committee recommended to our Board of Directors that the Compensation Discussion and Analysis be included in this proxy statement and also be incorporated by reference in our Annual Report on Form 10-K for the fiscal year ended July 31, 2008.

THE COMPENSATION COMMITTEE

Irwin W. Gerson, Chairman
Dr. Bernard L. Kasten
Melvin F. Lazar, CPA

Compensation Committee Interlocks and Insider Participation

The current members of the Compensation Committee are Messrs. Gerson, Sias and Lazar. No member of the Compensation Committee has a relationship that would constitute an interlocking relationship with the Company's executive officers or other directors.

Securities Authorized For Issuance Under Equity Compensation Plans

The following table sets forth information regarding our existing equity compensation plans as of July 31, 2008:

Plan Category	Number of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights (a)	Weighted Average Exercise Price of Outstanding Options, Warrants and Rights (b)	Number of Remainder Available Under Equity Plans (Exclud Reflected in (c)
Equity compensation plans approved by security holders(1)(3)	2,700,457(1)	\$13.32	
Equity compensation plans not approved by security holders	141,062(2)	\$14.15	590
Total	2,841,519		590

(1) Shares to be issued upon exercise of options under the 1994, 1999 and 2005 plans

(2) Unvested restricted shares under the 2005 plan

(3) Shares available for grant under the 1999 and 2005 plans.

Insurance for Indemnification of Directors and Officers

The Company has in effect with American International Group and XL Specialty Insurance Company, under a policy effective February 22, 2008 and expiring on February 21, 2009, insurance covering all of its directors and officers and certain other employees of the Company against certain liabilities and reimbursing the Company for obligations which it incurs as a result of its indemnification of such directors, officers and employees. Such insurance has been obtained in accordance with the provisions of Section 726 of the Business Corporation Law of the State of New York. The annual premium is \$260,000.

This report has been provided by the Board of Directors of the Company.

Elazar Rabbani, Ph.D.
 Barry W. Weiner
 Shahram K. Rabbani
 Irwin C. Gerson
 Dr. Bernard L. Kasten
 Stephen B.H. Kent, Ph.D
 Melvin F. Lazar, CPA
 John B. Sias

PROPOSAL 2
APPROVAL OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

The Board of Directors has appointed Ernst & Young LLP, as its independent registered public accounting firm, to audit the accounts of the Company for the fiscal year ending July 31, 2008. The Board of Directors approved the reappointment of Ernst & Young LLP (which has been engaged as the Company's independent registered public accounting firm since 1983). Ernst & Young LLP has advised the Company that neither the firm nor any of its members or associates has any direct financial interest in the Company or any of its affiliates other than as auditors. Although the selection and appointment of independent auditors is not required to be submitted to a vote of shareholders, the Directors deem it desirable to obtain the shareholders' ratification and approval of this appointment.

The following table sets forth the aggregate fees billed by Ernst & Young LLP for the years ended July 31, 2008 and 2007 for audit and non-audit services and are categorized as Audit Fees, Audit-Related Fees, Tax Fees and All Other Fees, which have all been pre-approved by the Audit Committee. The nature of the services provided in each such category is described following the table,

	2008	2007
Audit Fees	\$ 919,000	\$ 865,000
Audit-Related Fees	120,000	222,000
Tax Fees	10,000	10,000
All Other Fees	0	0
Total Fees	\$1,049,000	\$1,097,000

Audit Fees □ Consists of fees for professional services necessary to perform an audit or review in accordance with the Public Company Accounting Oversight Board, including services rendered for the audit of our annual financial statements (including services incurred with rendering an opinion under Section 404 of the Sarbanes-Oxley Act of 2002) and quarterly reviews of the Company's interim financial statements. Audit fees also include fees for services performed by Ernst & Young LLP that are closely related to the audit and in many cases could only be provided by the Company's independent registered public accountants. Such services include the issuance of consents related to the Company's registration statements and capital raising activities, assistance with and review of other documents filed with the Commission and accounting advice on completed transactions.

Audit-Related Fees □□ Audit-related fees in fiscal 2008 and 2007 related to Merger & Acquisition due diligence performed in connection with acquisitions in both fiscal years.

Tax Fees □ During fiscal 2008 and 2007, Ernst & Young LLP performed certain tax compliance services.

All Other Fees □ There were no professional services rendered by Ernst & Young LLP that would be classified as other fees during the years ended July 31, 2008 and 2007.

Pre-Approval Policies and Procedures - The Audit Committee has adopted a policy that requires advance approval of all audit, audit-related, tax services, and other services performed by the independent auditor. The policy provides for pre-approval by the Audit Committee of specifically defined audit and non-audit services. Unless the specific service has been previously pre-approved with respect to that year, the Audit Committee must approve the permitted service before the independent auditor is engaged to perform it. The Audit Committee has delegated to the Chair of the Audit Committee authority to approve permitted services provided that the Chair reports any decisions to the Audit Committee at its next scheduled meeting.

In making its recommendations to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accountants for the fiscal year ending July 31, 2009, the Audit Committee has considered whether the services provided by Ernst & Young LLP are compatible with maintaining the independence of Ernst & Young LLP.

Representatives of Ernst & Young LLP are expected to be present at the Annual Meeting with the opportunity to make a statement if they desire to do so and are expected to be available to respond to appropriate questions.

THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR PROPOSAL 2 RELATING TO THE RATIFICATION OF THE APPOINTMENT OF THE AUDITORS. PROXIES SOLICITED BY THE BOARD OF DIRECTORS WILL BE SO VOTED UNLESS SHAREHOLDERS SPECIFY IN THEIR PROXIES A CONTRARY CHOICE.

GENERAL

The Management of the Company does not know of any matters other than those stated in this Proxy Statement which are to be presented for action at the meeting. If any other matters should properly come before the meeting, it is intended that proxies in the accompanying form will be voted on any such matters in accordance with the judgment of the persons voting such proxies. Discretionary authority to vote on such matters is conferred by such proxies upon the persons voting them.

The Company will bear the cost of preparing, assembling and mailing the Proxy, Proxy Statement and other material which may be sent to the shareholders in connection with this solicitation. In addition to the solicitation of proxies by use of the mails, officers and regular employees may solicit the return of proxies. The Company may reimburse persons holding stock in their names or in the names of other nominees for their expense in sending proxies and proxy material to principals. In addition, American Stock Transfer & Trust Company, 59 Maiden Lane, New York, New York 10038, the Company's transfer agent, has been engaged to solicit proxies on behalf of the Company for a fee, excluding expenses, of approximately \$5,000. Proxies may be solicited by mail, personal interview, telephone and telegraph.

Enzo Website

In addition to the information about the Company and its subsidiaries contained in this proxy statement, extensive information about the Company can be found on our website located at www.enzo.com, including information about our management team, products and services and our corporate governance practices.

The corporate governance information on our website includes the Company's Corporate Governance Guidelines, the Code of Conduct and the charters of each of the committees of the Board of Directors. These documents can be accessed at www.enzo.com. Printed versions of our Corporate Governance Guidelines, our Code of Conduct and the charters for our Board committees can be obtained, free of charge, by writing to the Company at: 527 Madison Avenue, New York, New York 10022, Attn: Corporate Secretary.

This information about Enzo's website and its content, together with other references to the website made in this proxy statement, is for information only and the content of the Company's website is not deemed to be incorporated by reference in this proxy statement or otherwise filed with the Securities and Exchange Commission.

The Company will provide without charge to each person being solicited by this Proxy a copy of the Annual Report of the Company on Form 10-K for the year ended July 31, 2008 (as filed with the Securities and Exchange Commission) including the financial statements and the schedules thereto. All such requests should be directed to Shahram K. Rabbani, Secretary, Enzo Biochem, Inc., 527 Madison Avenue, New York, New York 10022.

SHAREHOLDER PROPOSALS AND DIRECTOR NOMINATIONS TO BE PRESENTED AT THE NEXT ANNUAL MEETING

Shareholder Proposals. Proposals of shareholders intended to be included in the Company's proxy statement and form of proxy for use in connection with the Company's 2009 Annual Shareholder Meeting must be received by the Company's Secretary at the Company's principal executive offices at 527 Madison Avenue, New York, New York 10022, no later than August 7, 2009 (120 days preceding the one-year anniversary of the date this proxy statement was first mailed to our shareholders for the 2008 Annual Shareholder Meeting), and must otherwise satisfy the procedures prescribed by Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"). It is suggested that any such proposals be submitted by certified mail, return receipt requested.

Pursuant to Rule 14a-4 under the Exchange Act, shareholder proxies obtained by our Board of Directors in connection with our 2009 Annual Shareholder Meeting will confer on the named proxies discretionary authority to vote on any matters presented at the annual meeting which were not included in the Company's proxy statement in connection with such annual meeting, unless notice of the matter to be presented at the annual meeting is provided to the Company's Secretary before October 21, 2009 (the 45th day preceding the one-year anniversary of the date this proxy statement was first mailed to our shareholders for the 2008 Annual Shareholder Meeting).

Director Nominations. Under our Bylaws, shareholders intending to nominate one or more candidates for election to our Board of Directors at our 2009 Annual Shareholder Meeting may do so only if written notice of the intent to make such nomination(s) has been given, either by personal delivery or by United States mail, postage prepaid, to the Secretary of the Company, at the Company's principal executive offices at 527 Madison Avenue, New York, New York 10022, not later than 60 days in advance of the date of such annual meeting. We have not yet set the date for our 2009 Annual Shareholder Meeting. For illustration purposes only, however, if our 2009 Annual Shareholder Meeting were to be held on January 22, 2010, to be timely, such notice of an intent to make such nomination(s) would have to be received by the Company's Secretary in the manner set forth above not later than November 23, 2009 (60 days in advance of the date of such meeting). Such notice must contain all of the information required by our Bylaws, including, without limitation, all information that would be required in connection with such nomination(s) under the Securities and Exchange Commission's proxy rules if such nomination were the subject of a proxy solicitation and the written consent of each nominee for election to our Board of Directors named therein to serve if elected. The chairman of the meeting may refuse to acknowledge the nomination of any person not made in compliance with our Bylaws.

By Order of the Board of Directors

Shahram K. Rabbani, Secretary
Dated: November 28, 2008

FORM OF PROXY
ENZO BIOCHEM, INC.

527 Madison Avenue
New York, New York 10022

THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS

The undersigned hereby appoints Barry Weiner and Dr. Stephen Kent as Proxies, each with the power to appoint his substitute, and hereby authorizes them to represent and to vote, as designated on the reverse side, all the shares of the Common Stock of Enzo Biochem, Inc. held of record by the undersigned on November 25, 2008, at the Annual Meeting of Shareholders to be held on January 22, 2009 or at any adjournment or postponement thereof.

(Continued and to be signed on the reverse side)

14475

ANNUAL MEETING OF SHAREHOLDERS OF

ENZO BIOCHEM, INC.

January 22, 2009

Please sign, date and mail
your proxy card in the
envelope provided as soon
as possible.

Please detach along perforated line and mail in the envelope
provided.

10030000000000000000 3

012209

**THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR THE ELECTION OF THE NOMINEE FOR CLASS THREE
DIRECTOR IN PROPOSAL ONE AND FOR PROPOSAL 2.**

**PLEASE SIGN, DATE AND RETURN PROMPTLY IN THE ENCLOSED ENVELOPE. PLEASE MARK YOUR VOTE IN BLUE OR
BLACK INK AS SHOWN HERE S**

1. Election of Class III
Director:

2. To ratify the appointment of Ernst &
Young LLP as the Company's
independent registered public accounting
firm for the Company's fiscal year ending
July 31, 2009.

FOR AGAINST ABSTAIN

FOR THE NOMINEE

NOMINEE:

Elazar Rabbani, Ph.D.

In their discretion, the Proxies are authorized to vote upon such
other business as may properly come before the Annual Meeting.
This proxy when properly executed will be voted in the manner
directed herein by the undersigned shareholder. If no direction is
made, this proxy will be voted FOR Proposals 1 and 2.

**WITHHOLD AUTHORITY
FOR THE NOMINEE**

PLEASE SIGN EXACTLY AS NAME APPEARS BELOW. WHEN SHARES
OF COMMON STOCK ARE HELD BY JOINT TENANTS, BOTH SHOULD
SIGN.

To change the address on your account, please
check the box at right and indicate your new address
in the address space above. Please note that
changes to the registered name(s) on the account
may not be submitted via this method.

Edgar Filing: ENZO BIOCHEM INC - Form DEF 14A

Signature of Shareholder

Date:

Signature of Shareholder

Date:

Note: Please sign exactly as your name or names appear on this Proxy. When shares are held jointly, each holder should sign. When signing as executor, administrator, attorney, trustee or guardian, please give full title as such. If the signer is a corporation, please sign full corporate name by duly authorized officer, giving full title as such. If signer is a partnership, please sign in partnership name by authorized person.
